In this engaging podcast, Drs. Bradley Monk and Robert Burger discuss important practical issues regarding the use of antiangiogenic therapy to treat epithelial ovarian cancer, including the possible value of targeted agents as maintenance therapy, the correct dosage and duration of targeted therapy, and the role of CA125 in determining tumor progression with a biologic agent

The experts discuss the continued use of bevacizumab and/or other targeted agents in treating recurrent disease.

Using Targeted Therapies in a Real-World Setting - Part 2

Two experts discuss the practical use of bevacizumab in epithelial ovarian cancer and the particular benefit observed in this cancer compared to activity in solid tumors.